PCRX — Pacira BioSciences, Inc.

Summary of Pacira BioSciences, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Achieved $726 million for the full year 2025, with Q4 revenue of $155.8 million for EXPAREL, up from $147.7 million in Q4 2024.
• Gross Margin: Non-GAAP gross margin improved to 80% in Q4 2025, up from 79% in Q4 2024, driven by enhanced manufacturing efficiencies.
• R&D and SG&A Expenses: Non-GAAP R&D expenses rose to $34.4 million in Q4 from $22 million in 2024. Non-GAAP SG&A expenses increased to $91.9 million from $70.6 million, impacted by unexpected business development costs and litigation.
• Cash Position: Exited Q4 with $238 million in cash and investments, supporting ongoing growth initiatives.

2. Strategic Updates and Business Highlights

• Five-by-30 Strategy: Focused on helping 3 million patients annually by 2030, with current patient reach at 2.5 million.
• Partnerships: Secured a partnership with LG Chem for EXPAREL in Asia Pacific, expected to generate revenue starting in 2027. The partnership with J&J MedTech is anticipated to enhance ZILRETTA's market reach.
• Pipeline Development: Advancements in pipeline programs including PCRX-201 and PCRX-2002, with key clinical milestones expected in 2026.
• NO PAIN Initiative: Expanded access to EXPAREL, now covering 102 million lives outside the surgical bundle, facilitating a shift in opioid prescribing patterns.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Projected total revenue of $745 million to $770 million, with EXPAREL sales expected between $600 million and $620 million.
• Gross Margins: Anticipated non-GAAP gross margins of 77% to 79% for 2026, with expectations for steady annual increases.
• Expense Projections: Non-GAAP R&D expenses projected at $105 million to $115 million, and SG&A expenses at $320 million to $340 million.

4. Bad News, Challenges, or Points of Concern

• Market Conditions: Anticipated challenges in the first quarter of 2026 due to adverse weather impacting elective procedures, which could affect sales.
• ZILRETTA Performance: Sales for ZILRETTA were flat in 2025, attributed to a focus on EXPAREL and restructuring sales forces, which may continue to pose challenges in establishing growth.
• Increased Expenses: Rising R&D and SG&A expenses may pressure profitability if not managed effectively.

5. Notable Q&A Insights

• Efficacy Trends for PCRX-201: The focus of the upcoming Phase II study is on safety, with secondary endpoints assessing pain and function. The results will be contextualized against existing data from the IGOR registry.
• Factors Influencing Revenue Guidance: The guidance reflects a conservative approach due to potential headwinds in the elective procedure market, with room for upside as market dynamics evolve.
• Adoption vs. Reimbursement: The company is seeing positive sentiment around EXPAREL, but barriers to adoption remain, primarily related to clinical adoption rather than reimbursement issues.

Overall, Pacira BioSciences is positioned for growth with a solid revenue outlook and strategic initiatives, though it faces challenges in market conditions and expense management.